Literature DB >> 22158075

Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.

Adriana Handra-Luca1, Claude Lesty, Pascal Hammel, Alain Sauvanet, Vinciane Rebours, Antoine Martin, Remi Fagard, Jean-François Fléjou, Sandrine Faivre, Pierre Bédossa, Philippe Ruszniewski, Anne Couvelard.   

Abstract

OBJECTIVES: The aims of this study were to study the biological and clinical significance of 3 main proteins of the mitogen-activated protein kinase (MAPK) signaling pathway, ERK1/2, P38, and MKK4, in a series of patients having pancreatic adenocarcinomas treated by surgery.
METHODS: We examined the immunohistochemical expression of 3 MAPK proteins, ERK1/2, P38, and MKK4 in 99 surgically resected pancreatic ductal adenocarcinomas. Tumor protein expression was studied with regard to pathological characteristics and to postsurgical recurrence-free and overall survivals.
RESULTS: MKK4 expression was related to tumor cell proliferation, evaluated by the Ki67 index (P < 0.01). ERK1/2 expression was related to a shorter recurrence-free survival on both univariate and multivariate analysis (P < 0.01; odds ratio, 8.39; 95% confidence interval, 2.68-26.26) independently of lymph node metastases and tumor size, and to a shorter overall survival (P = 0.01) on univariate analysis. In patients without postsurgical treatment, both ERK1/2 and P38 tumor expression correlated with a shorter recurrence-free survival (P < 0.01 and P = 0.02, respectively).
CONCLUSIONS: The results of our study suggest that in pancreatic ductal adenocarcinomas, the MKK4 protein was directly related to high cell proliferation, and that tumor ERK1/2 and P38 expression correlated to shorter postsurgical recurrence-free and overall survivals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22158075     DOI: 10.1097/MPA.0b013e318238379d

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  13 in total

1.  Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Ioly Kotta-Loizou; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Eougken Dana; Jose Rodriguez; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Tumour Biol       Date:  2014-03-30

Review 2.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

3.  Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival.

Authors:  Yi Zhong; Yoshiki Naito; Leslie Cope; Salvador Naranjo-Suarez; Tyler Saunders; Seung-Mo Hong; Michael G Goggins; Joseph M Herman; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

4.  P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.

Authors:  Gabriel G Vega; Alejandro Avilés-Salas; J Ramón Chalapud; Melisa Martinez-Paniagua; Rosana Pelayo; Héctor Mayani; Rogelio Hernandez-Pando; Otoniel Martinez-Maza; Sara Huerta-Yepez; Benjamin Bonavida; Mario I Vega
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

5.  The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.

Authors:  Scott W Malm; Neale T Hanke; Alexander Gill; Liliana Carbajal; Amanda F Baker
Journal:  J Exp Clin Cancer Res       Date:  2015-04-01

6.  Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.

Authors:  Charles S Goldsmith; Sam Moon Kim; Nirmala Karunarathna; Nichole Neuendorff; L Gerard Toussaint; David J Earnest; Deborah Bell-Pedersen
Journal:  BMC Cancer       Date:  2018-01-10       Impact factor: 4.430

7.  A novel 20-gene prognostic score in pancreatic adenocarcinoma.

Authors:  Seçil Demirkol Canlı; Ege Dedeoğlu; Muhammad Waqas Akbar; Barış Küçükkaraduman; Murat İşbilen; Özge Şükrüoğlu Erdoğan; Seda Kılıç Erciyas; Hülya Yazıcı; Burçak Vural; Ali Osmay Güre
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

Review 8.  MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.

Authors:  Tao Xia; Xiao-Yi Chen; You-Ni Zhang
Journal:  Mol Cell Biochem       Date:  2021-07-29       Impact factor: 3.396

Review 9.  MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.

Authors:  Afra Z Daoud; Eoghan J Mulholland; Grace Cole; Helen O McCarthy
Journal:  BMC Cancer       Date:  2019-11-21       Impact factor: 4.430

10.  Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.

Authors:  Linda Sooman; Johan Lennartsson; Joachim Gullbo; Michael Bergqvist; Georgios Tsakonas; Fredrik Johansson; Per-Henrik Edqvist; Fredrik Pontén; Archita Jaiswal; Sanjay Navani; Irina Alafuzoff; Svetlana Popova; Erik Blomquist; Simon Ekman
Journal:  Med Oncol       Date:  2013-06-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.